---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-117308"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:34:33.106558+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eloxx reports Q3 net loss of $3.6M; positive Phase 2 data for ELX-02; Nasdaq delisting appeal pending

## Summary
- Net loss of $3.6M ($1.31/share) vs. $7.5M loss a year ago; R&D expenses down to $1.3M from $4.9M.
- Cash of $4.8M as of Sep 30; raised $3.8M in Q3; cash expected to fund operations only through end of Q4 2023.
- Phase 2 open-label trial of ELX-02 in Alport Syndrome showed improved kidney morphology, collagen expression, and average 60% increase in filtration slit density.
- Strategic partnership progress for ZKN-013; FDA clearance received for single ascending dose trial.
- Common stock suspended on Nasdaq on Oct 16 and now trades on OTC Pink; appeal of delisting decision pending.

## SEC filing metadata
- accession: 0001104659-23-117308
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923117308/0001104659-23-117308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923117308/tm2330576d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-117308
- JSON: https://secwatch.observer/filing/0001104659-23-117308.json
- Plain text: https://secwatch.observer/filing/0001104659-23-117308.txt

## Key facts
- Earnings Releases
  Eloxx Pharmaceuticals, Inc. reported third fiscal quarter ended September 30, 2023 results: net income $3.6 million, EPS $1.31 per share.
  - Period: third fiscal quarter ended September 30, 2023
  - Net income: $3.6 million
  - EPS: $1.31 per share
  - Result: reported results
  source text: For the three months ended September 30, 2023, we incurred a net loss of $3.6 million, or $1.31 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465923117308/0001104659-23-117308-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.